Cerus Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
43,337.00
38,755.00
55,868.00
62,906.00
60,585.00
57,564
Depreciation, Depletion & Amortization
557.00
1,415.00
1,699.00
1,817.00
1,811.00
1,445
Other Funds
18,398.00
2,421.00
281.00
8,482.00
10,265.00
11,647
Funds from Operations
24,355.00
39,735.00
53,881.00
52,579.00
48,628.00
44,468
Changes in Working Capital
2,442.00
76.00
2,752.00
950.00
3,607.00
13,222
Net Operating Cash Flow
26,797.00
39,811.00
51,129.00
53,529.00
52,235.00
31,246
Capital Expenditures
678.00
2,106.00
722.00
563.00
353.00
Purchase/Sale of Investments
28,379.00
1,241.00
2,238.00
19,361.00
774.00
Net Investing Cash Flow
29,057.00
3,347.00
1,516.00
19,924.00
421.00
Issuance/Reduction of Debt, Net
4,466.00
6,374.00
9,887.00
622.00
10,375.00
Net Financing Cash Flow
58,643.00
36,454.00
97,954.00
24,567.00
43,000.00
Net Change in Cash
2,789.00
6,704.00
48,341.00
48,886.00
8,814.00
Free Cash Flow
27,460.00
41,917.00
51,851.00
54,092.00
52,588.00
Deferred Taxes & Investment Tax Credit
27.00
26.00
7.00
28.00
119.00
4
Change in Capital Stock
63,109.00
30,080.00
88,067.00
25,189.00
32,625.00

About Cerus

View Profile
Address
2550 Stanwell Drive
Concord California 94520
United States
Employees -
Website http://www.cerus.com
Updated 07/08/2019
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. It produces blood system for platelets and plasma. It markets its products under the INTERCEPT brand.